







an Open Access Journal by MDPI

# Flow Cytometry in Cancer Research

Guest Editors:

### **Dr. George Vartholomatos**

Unit of Molecular Biology, Hematology Laboratory, University General Hospital of Ioannina, Ioannina, Greece

#### Dr. Lefkothea Dova

Unit of Molecular Biology, Haematology Laboratory, University General Hospital of Ioannina, Ioannina, Greece

### Dr. Georgios S. Markopoulos

Neurosurgical Institute, University of Ioannina, Ioannina, Greece

Deadline for manuscript submissions:

30 November 2024

## **Message from the Guest Editors**

The aim of the current Special Issue, "Flow Cytometry in Cancer Research", is to define the state-of-the-art in the field as well as to present recent flow cytometry innovations with an application in cancer research. We wish to serve as a forum for researchers applying flow cytometry in oncology, leading to knowledge dissemination in the fight against this devastating disease.

We are welcoming primary or review articles covering, but not limited to, the following topics:

- Reviews describing the state-of-the-art in the field;
- The contribution of cytometry in basic and translational cancer research;
- Novel methodologies for phenotypic analysis of cancer;
- Clinical or animal models that incorporate flow cytometry analyses;
- Technological and methodological advances of diagnostic techniques (for example, multiparametric analysis in hematology, oncology, immunology, etc.).













an Open Access Journal by MDPI

### **Editor-in-Chief**

#### Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

## **Message from the Editor-in-Chief**

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

### **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

#### **Contact Us**